- Scientists have developed a new AI model, PhenMap, to identify which advanced bowel cancer patients would best respond to the targeted drug bevacizumab.
- Bevacizumab, approved for advanced bowel cancer on the NHS, is effective for only a small group of patients and carries a risk of serious side effects.
- Developed by researchers at the Institute of Cancer Research (ICR) in London and RCSI University of Medicine and Health Sciences in Dublin, PhenMap integrates complex genetic and clinical data to predict drug response.
- The tool aims to prevent patients from undergoing ineffective treatment and suffering unnecessary side effects by identifying those unlikely to benefit.
- This AI-driven approach could revolutionise cancer research by enabling more precise patient stratification and has potential for use with other targeted therapies.
IN FULL
